Acting General Director of Technopark “Idea” Oleg Ibragimov visited India with the working visit as part of the delegation of the Republic of Tatarstan. On April 16-17, 2018 representatives of our republic, led by the President Rustam Minnikhanov, visited the leading centers of Indian industry - Hyderabad (the capital of the states of Telangana and Andhra Pradesh) and Visakhapatnam (Andhra Pradesh).
During the visit, the delegation visited a pharmaceutical cluster “Farm City”, where it got acquainted with a number of productions, and the Indian science city HITEC City. Also, a number of meetings were held with Indian politicians and businessmen, including in the framework of the forum “Andhra Pradesh-Tatarstan”.
Noting the possibilities of cooperation between Tatarstan and India in the field of pharmaceuticals, the President noted that the pharmaceutical industry is quite well developed in the republic. It is represented by the centers of development in universities and the operating enterprises-leaders of the TOP-20 pharmaceutical companies of Russia - JSC “Tatchempharmpreparaty” and “Nanopharma Development” LLC.
Recall that the project “Nanopharma Development” is a joint project implemented in Kazan jointly by JSC “Rusnano”, Innovative Technopark “Idea”, the Republic of Tatarstan and “Izvarino Pharma” LLC in 2013. The plant is part of the nanotechnology cluster and is the key project in the direction of pharmacy.
The uniqueness of the project is to equip the plant with the most up-to-date research and production equipment that allows to develop and carry out industrial production of medicines in such vital areas as oncology, transplantology and treatment of HIV infection.
In 2016, the first production line was launched, intended for the release of solid dosage forms (tablets, capsules). All production processes are made in insulator design, which allows the plant to produce medicines containing cytotoxic and highly active substances.
The portfolio of products is formed according to the state program of import substitution of vital and essential medicines (VED). The development of some of the drugs was carried out with the support of the Ministry of Industry and Trade of the Russian Federation. Currently, the plant produces two drugs - Tacrolimus (a drug used in transplantology) and Imatinib (cytotoxic for the treatment of leukemia in adults and children). The company plans to expand its portfolio to 10 positions in the near future. All preparations planned for production have been developed and are at the stage of clinical studies.
Since 2017, the second phase has been launched - the construction and commissioning of a line for the production of sterile dosage forms, which will be used to produce hormonal drugs for the treatment of female infertility and other vital drugs in the form of injections.
